Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BioCryst ( (BCRX) ) is now available.
In the third quarter of 2025, BioCryst Pharmaceuticals reported significant financial growth, with ORLADEYO net revenue reaching $159.1 million, a 37% increase year-over-year. The company completed the sale of its European ORLADEYO business, using proceeds to retire Pharmakon term debt, and announced a definitive agreement to acquire Astria Therapeutics, expected to close in the first quarter of 2026. These strategic moves are expected to enhance BioCryst’s market position and financial stability, with the company raising its full-year revenue guidance and lowering its operating expense outlook for 2025.
The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative equity. While the earnings call provided positive insights with strong ORLADEYO performance and strategic moves, the technical indicators and valuation concerns weigh down the score.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of oral treatments for rare diseases. Its primary product, ORLADEYO, is an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks.
Average Trading Volume: 4,164,093
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.54B
For an in-depth examination of BCRX stock, go to TipRanks’ Overview page.